Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark.
J Antimicrob Chemother
; 77(11): 3126-3129, 2022 10 28.
Article
en En
| MEDLINE
| ID: mdl-36048620
ABSTRACT
OBJECTIVES:
To determine the phenotypic and genotypic antibiotic susceptibility of Mycoplasma amphoriforme isolates recovered from patients in the UK and Denmark.METHODS:
Seven isolates of M. amphoriforme were examined for antimicrobial susceptibility to seven antibiotics using the microbroth dilution assay in line with the CLSI guidelines for mycoplasmas. Each isolate was additionally subjected to WGS to identify resistance-associated mutations. Based on the consensus sequences from the genomic data, PCR primers were designed, and tested, for the amplification of the QRDR within the parC gene.RESULTS:
Of the seven isolates investigated, four (57%) were resistant to moxifloxacin (0.5-1â mg/L) and levofloxacin (1-2â mg/L), compared with those that were susceptible (0.03-0.06 and 0.006â mg/L, respectively). Isolate H29 was resistant to five of the seven antibiotics tested moxifloxacin, 0.5â mg/L; levofloxacin, 2â mg/L; azithromycin, 64â mg/L; erythromycin, 128â mg/L; and clindamycin, 64â mg/L. All isolates were susceptible to tetracycline (0.06â mg/L) and lefamulin (0.001-0.004â mg/L). Mutations from genomic data confirmed the presence of an S89F mutation within the ParC protein among all fluoroquinolone-resistant isolates and an A2059G mutation in the 23S rRNA gene in the macrolide- and lincosamide-resistant isolate H29.CONCLUSIONS:
To the best of our knowledge, this is the first time where phenotypic and genotypic resistance data have been paired for M. amphoriforme confirming a correlation between the two. These data suggest the need for focused testing and resistance determination of isolates from high-risk patients given the backdrop of a high prevalence of antimicrobial resistance.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Levofloxacino
/
Antibacterianos
Tipo de estudio:
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
J Antimicrob Chemother
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido